^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    EGFR inhibitor

    Related drugs:
    1d
    Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study (clinicaltrials.gov)
    P2, N=173, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Tagrisso (osimertinib)
    1d
    NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=29, Active, not recruiting, University of Colorado, Denver | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • NT219
    2d
    Taxanes Versus Pemetrexed After Osimertinib Resistance in EGFR-Mutated NSCLC: A Retrospective Cohort with Two-Model In Vitro Validation. (PubMed, Cancer Manag Res)
    Taxane‑based chemotherapy was associated with more favorable outcomes than pemetrexed in dramatic progression after osimertinib resistance, with higher non‑hematologic toxicity. These findings, supported by exploratory in vitro sensitivity, warrant prospective validation.
    Preclinical • Retrospective data • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • pemetrexed
    2d
    Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis. (PubMed, JTO Clin Res Rep)
    EGFR tyrosine kinase inhibitors, including osimertinib, generally exhibit lower efficacy in patients with the L858R-mutant NSCLC compared with those with exon 19 deletion (del19). Grade more than or equal to 3 adverse events occurred in 42% of patients. In real-world settings, RAM plus ERL demonstrated favorable efficacy in patients with L858R-mutant NSCLC and manageable toxicity.
    Retrospective data • Journal • Real-world evidence
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • erlotinib • Cyramza (ramucirumab)
    4d
    Frequent RBM10 Comutation and a Mutually Exclusive Relationship With Other TP53 Pathway Aberrations in Early-Stage Non-Small-Cell Lung Cancer with EGFR Mutation. (PubMed, Clin Lung Cancer)
    RBM10 mutation is frequent in Japanese patients with NSCLC with EGFR mutation, especially those with L858R or uncommon mutations, and was associated with late-onset and features of indolent tumor growth.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase) • RBM10 (RNA Binding Motif Protein 10)
    |
    TP53 mutation • EGFR mutation • EGFR L858R
    |
    Tagrisso (osimertinib)
    4d
    CDDO-Me alleviates doxorubicin/lapatinib-induced cardiotoxicity by activating the NRF2/GPX4 axis to inhibit oxidative stress and ferroptosis. (PubMed, Free Radic Biol Med)
    Furthermore, CDDO-Me did not compromise the antitumor efficacy of DOX/LAP in breast cancer cells. CDDO-Me protects against DOX/LAP-induced cardiotoxicity by stabilizing GPX4 and inhibiting ferroptosis, offering a promising therapeutic strategy that preserves cardiac function without interfering with chemotherapy.
    Journal
    |
    GPX4 (Glutathione Peroxidase 4)
    |
    lapatinib • doxorubicin hydrochloride
    4d
    FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorectal Cancer (clinicaltrials.gov)
    P2/3, N=220, Not yet recruiting, Shanghai 10th People's Hospital
    New P2/3 trial
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • irinotecan
    4d
    Osimertinib In EGFR Mutant Lung Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Mar 2027 --> Mar 2028 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib)
    4d
    ERBB2 activating mutations and co-occurring genomic alterations contribute to disease heterogeneity in patients with ERBB2-mutant lung cancer. (PubMed, J Thorac Oncol)
    NSCLCs harboring ECD-ERBB2 mutations are associated with a unique clinico-genomic phenotype and improved outcomes with first-line chemoimmunotherapy. These findings have implications for optimizing treatment strategies in this disease.
    Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • RBM10 (RNA Binding Motif Protein 10)
    |
    KRAS mutation • EGFR mutation • PIK3CA mutation • HER-2 mutation • STK11 mutation • KEAP1 mutation
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • Hernexeos (zongertinib) • Hyrnuo (sevabertinib)
    4d
    HIF-1α siRNA Enhances the Efficacy of Erlotinib in Non-small Cell Lung Cancer: A Novel Strategy to Reverse Hypoxia-Induced Drug Resistance. (PubMed, Drugs R D)
    Targeting HIF-1α disrupts metabolic reprogramming and hypoxia adaptation, thereby enhancing erlotinib efficacy. This combined approach highlights the therapeutic potential of HIF-1α inhibition as a novel strategy to overcome EGFR-TKI resistance in NSCLC.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit)
    |
    erlotinib
    5d
    Prognostic Impact of Cetuximab-Related Hypomagnesemia and Hypokalemia in RAS/RAF Wild-Type Colorectal Cancer: A Multicenter Study. (PubMed, Cancer Manag Res)
    Moreover, hypokalemia was linked to improved disease control. These results provide incremental evidence regarding the clinical relevance of electrolyte disturbances, particularly hypokalemia, and highlight the need for prospective studies to clarify their prognostic and predictive significance.
    Clinical • Journal
    |
    RAS (Rat Sarcoma Virus)
    |
    Erbitux (cetuximab)
    5d
    Case Report: A case of severe hypotension induced by nimotuzumab in a nasopharyngeal carcinoma patient. (PubMed, Front Immunol)
    After discontinuing the drug and giving continuous norepinephrine to increase BP, the patient's BP returned to stable. This case suggests that although nimotuzumab-related hypotension is mostly mild and reversible, BP monitoring should still be strengthened to maintain vigilance against severe hypotension and intervene promptly in clinical practice.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression • EGFR positive
    |
    TheraCIM (nimotuzumab)